The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
Open accessAbstract
Summary BRAF is an attractive target for melanoma drug development. However, resistance to BRAF inhibitors is a significant clinical challenge. We describe a model of resistance to BRAF inhibitors developed by chronic treatment of BRAFV600E melanoma cells with the BRAF inhibitor SB-590885; these cells are cross resistant to other BRAF-selective inhibitors. Resistance involves flexible switching among the three RAF isoforms, underscoring the ability of melanoma cells to adapt to pharmacological challenges. IGF-1R/PI3K signaling was enhanced in resistant melanomas, and combined treatment with IGF-1R/PI3K and MEK inhibitors induced death of BRAF inhibitor-resistant cells. Increased IGFR-1R and pAKT levels in a post-relapse human tumor sample are consistent with a role for IGF-1R/PI3K-dependent survival in the development of resistance to BRAF inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 2×
“Over 50%ofmelanomas harbor activating V600E mutations in BRAF (BRAFV600E) (Davies et al., 2002), an oncogene known to be critical for the proliferation and survival of melanoma cells through activation of the RAF/MEK/ERK mitogen activated protein kinase pathway (MAPK) (Dhomen and Marais, 2009;…”
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 1×
“Drug resistance is a common problem associated with chronic treatment with anticancer drugs (Engelman and Janne, 2008; Engelman et al., 2007; Kobayashi et al., 2005; Pao et al., 2005).”
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Self-citationA Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
SEER Cancer Statistics Review, 1975-2008, National Cancer Institute, Bethesda, MD
Howlader, N. (2011) · Medical Entomology and Zoology · Cited by 2,612
Insulin and insulin-like growth factor signalling in neoplasia
Pollak, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2536 · Cited by 2,059 · cited 1×
“IGF-1R plays an important role in tumorigenesis, resistance to apoptosis and resistance to anti-cancer agents (Casa et al., 2008; Pollak, 2008; Tao et al., 2007).”
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W., Zhang, C., Zhang, Y., Habets, G., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,831
Self-citationRAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M., & Rosen, N. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,811
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Hatzivassiliou, G., Song, K., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,622
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Heidorn, S. J., Milagre, C., Whittaker, S., Nourry, A., Niculescu-Duvas, I., Dhomen, N., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,465
Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346
Self-citationGarnett, M. J., & Marais, R. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.022 · Cited by 799
Engelman, J. A., & Jänne, P. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2248 · Cited by 703
Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
Montagut, C., Sharma, S. V., Shioda, T., McDermott, U., Ulman, M., Ulkus, L. E., Dias-Santagata, D., Stubbs, H., Lee, D. Y., Singh, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6787 · Cited by 508
Smalley, K. S. M., Haass, N. K., Brafford, P. A., Lioni, M., Flaherty, K. T., & Herlyn, M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0084 · Cited by 463
Self-citationSuppression of BRAF(V599E) in human melanoma abrogates transformation.
Hingorani, S. R., Jacobetz, M. A., Robertson, G. P., Herlyn, M., & Tuveson, D. A. (2003) · PubMed · Cited by 455
Self-citationRecent Trends in Cutaneous Melanoma Incidence Among Whites in the United States
Jemal, A., Devesa, S. S., Hartge, P., & Tucker, M. A. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.9.678 · Cited by 449
Satyamoorthy, K., Li, G., Gerrero, M. R., Brose, M. S., Volpe, P., Weber, B. L., Belle, P. A. V., Elder, D. E., & Herlyn, M. (2003) · PubMed · Cited by 445
Self-citationMirzoeva, O. K., Das, D., Heiser, L. M., Bhattacharya, S., Siwak, D., Gendelman, R., Bayani, N., Wang, N. J., Neve, R. M., Guan, Y., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3389 · Cited by 385
Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin
Knight, S. D., Adams, N. D., Burgess, J. L., Chaudhari, A. M., Darcy, M. G., Donatelli, C. A., Luengo, J. I., Newlander, K. A., Parrish, C. A., Ridgers, L. H., et al. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml900028r · Cited by 373
Cyclolignans as Inhibitors of the Insulin-Like Growth Factor-1 Receptor and Malignant Cell Growth
Girnita, A., Girnita, L., Prete, F. D., Bartolazzi, A., Larsson, O., & Axelson, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2522 · Cited by 363
3-D Tumor Model for In Vitro Evaluation of Anticancer Drugs
Horning, J. L., Sahoo, S. K., Vijayaraghavalu, S., Dimitrijevic, S., Vasir, J. K., Jain, T. K., Panda, A. K., & Labhasetwar, V. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800047v · Cited by 292
Acquired resistance to tyrosine kinase inhibitors during cancer therapy
Engelman, J. A., & Settleman, J. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.01.004 · Cited by 284
King, A. J., Patrick, D. R., Batorsky, R. S., Ho, M. L., Do, H. T., Zhang, S. Y., Kumar, R., Rusnak, D. W., Takle, A. K., Wilson, D. M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2554 · Cited by 257
Self-citationFecher, L. A., Amaravadi, R. K., & Flaherty, K. T. (2008) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3282f5271c · Cited by 249
Tao, Y., Pinzi, V., Bourhis, J., & Deutsch, E. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0934 · Cited by 230
Molecular plasticity of human melanoma cells
Hendrix, M. J. C., Seftor, E. A., Hess, A. R., & Seftor, R. E. B. (2003) · Oncogene · doi:10.1038/sj.onc.1206447 · Cited by 223
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations
Smalley, K. S. M., Xiao, M., Villanueva, J., Nguyen, T. K., Flaherty, K. T., Letrero, R., Van Belle, P., Elder, D. E., Wang, Y., Nathanson, K. L., et al. (2009) · Oncogene · doi:10.1038/onc.2008.362 · Cited by 216
Self-citationPárrizas, M., Gazit, A., Levitzki, A., Wertheimer, E., & LeRoith, D. (1997) · Endocrinology · doi:10.1210/en.138.4.1427 · Cited by 212
Akt3 and Mutant V600EB-Raf Cooperate to Promote Early Melanoma Development
Cheung, M., Sharma, A., Madhunapantula, S. V., & Robertson, G. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5867 · Cited by 196
BRAF Signaling and Targeted Therapies in Melanoma
Dhomen, N., & Marais, R. (2009) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2009.04.001 · Cited by 195
Satyamoorthy, K., Li, G., Vaidya, B., Patel, D., & Herlyn, M. (2001) · PubMed · Cited by 195
Self-citationSumimoto, H., Miyagishi, M., Miyoshi, H., Yamagata, S., Shimizu, A., Taira, K., & Kawakami, Y. (2004) · Oncogene · doi:10.1038/sj.onc.1207812 · Cited by 194
Lee, J. T., Li, L., Brafford, P. A., van den Eijnden, M., Halloran, M. B., Sproesser, K., Haass, N. K., Smalley, K. S. M., Tsai, J., Bollag, G., et al. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00763.x · Cited by 166
Self-citationLasithiotakis, K. G., Sinnberg, T. W., Schittek, B., Flaherty, K. T., Kulms, D., Maczey, E., Garbe, C., & Meier, F. E. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.44 · Cited by 152
Mcl-1 Is Required for Melanoma Cell Resistance to Anoikis
Boisvert-Adamo, K., Longmate, W. M., Abel, E. V., & Aplin, A. E. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0358 · Cited by 137
Angelo, J. C. (2008) · Frontiers in bioscience · doi:10.2741/2925 · Cited by 133
Hilmi, C., Larribère, L., Giuliano, S., Bille, K., Ortonne, J. P., Ballotti, R., & Bertolotto, C. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701185 · Cited by 113
Iliopoulos, D., Ernst, C. S., Steplewski, Z., Jambrosic, J., Rodeck, U., Herlyn, M., Clark, W. H., Koprowski, H., & Herlyn, D. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.6.440 · Cited by 84
Self-citationLee, C., Park, K. H., Adachi, Y., et al. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700524 · Cited by 72
Yeh, A. H., Bohula, E. A., & Macaulay, V. M. (2006) · Oncogene · doi:10.1038/sj.onc.1209674 · Cited by 66
Karas, M., Danilenko, M., Fishman, D., LeRoith, D., Levy, J., & Sharoni, Y. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.26.16514 · Cited by 63
Discovery of an Oral Potent Selective Inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS)
Carron, C. P., Trujillo, J. I., Olson, K. L., et al. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml900025z · Cited by 24
Jones, R. J., Boyce, T., Fennell, M., Jacobs, V. N., Pinto, F., Duffield, E. L., Clack, G., Green, T., Kelly, J. D., & Robertson, J. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0440-9 · Cited by 18
Lipkin, G. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.69 · Cited by 14
Cited by
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationCancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
Konermann, S., Brigham, M. D., Trevino, A. E., Joung, J., Abudayyeh, O. O., Barcena, C., Hsu, P. D., Habib, N., Gootenberg, J. S., Nishimasu, H., et al. (2015) · Nature · doi:10.1038/nature14136 · Cited by 2,825
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Self-citationImproved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
Metadata
- Authors
- Villanueva, J., Vultur, A., Lee, J. T., Somasundaram, R., Fukunaga-Kalabis, M., Cipolla, A. K., Wubbenhorst, B., Xu, X., Gimotty, P. A., Kee, D., Santiago-Walker, A. E., Letrero, R., D'Andrea, K., Pushparajan, A., Hayden, J. E., Brown, K. D., Laquerre, S., McArthur, G. A., Sosman, J. A., Nathanson, K. L., & Herlyn, M.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2010-12
- Volume
- 18
- Issue
- 6
- Pages
- 683-695
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2100614336
- Cited by
- 1,259
- References
- 48
- FWCI
- 49.50
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.